SAVINGS AND SUPPORT

EASY-TO-APPLY PATIENT SAVINGS

With the SERNIVO Patient Savings Program, eligible patients can save on their SERNIVO Spray prescription

Eligible patients pay as little as $0. For more information, includinghow to request samples, sign up with the form below.

*Limitations apply. See eligibility rules for details.

WANT MORE INFORMATION
ABOUT SERNIVO?

* I would like to access the SERNIVO Co-pay Card and stay in touch with Encore Dermatology for any updates to the product line.
* 18 years of age or older

*Indicates required field

*First Name
*Last Name
*Email
*I am:
Address
City
State
ZIP Code
NPI #
Privacy Policy and Authorization
By clicking the submit button below, you consent to the use by Encore Dermatology of the information you have provided to periodically send you information about SERNIVO Spray or other products and promotions.

Encore Dermatology and its partners use the information you provide for legitimate business purposes only and will not sell, share, or otherwise distribute your personal information to third parties. By joining, you acknowledge that your consent to receive automated messages is not required as a condition to purchase goods and services

FREQUENTLY ASKED QUESTIONS

Which patients might benefit from SERNIVO?

SERNIVO is indicated for patients with mild-to-moderate plaque psoruasis, 18 years and older.
Enrolled patients had body surface area of involvment between 10% and 20%, and an Investigator’s Global Assessment (IGA) score of 3 (moderate)

How should patients apply SERNIVO?

Step 1: Shake the bottle
Remove the cap from the pump top.

 

Step 2: Push the pump
Hold the bottle upright. Point the opening of the pump top toward the affect area. To spray, push down on the pump top. NOTE: At first use, you may need to press the pump once or twice before SERNIVO can be sprayed.

 

Rub into skin
Spray only enough SERNIVO to cover the affected area.a Rub in gently. Replace the cap.

 

Download the complete Instructions for Use

What timepoints were used to measure safety and efficacy in clinical trials?

Adverse reactions and efficacy were assessed at Days 4, 8, 15 and 29. SERNIVO has been shown to be well-tolerated for patients to use for up to 4 weeks, as treatment duration in clinical trials did not extend beyond that time.

How is the SERNIVO formulation unique?

SERNIVO is the first oil-in-water emulsion (betamethasone dipropionate) delivered as a spray, making it a highly versatile topical. The patented SERNIVO formulation has been proven to penetrate and permeate skin layers.1,2

What are the ingredients in SERNIVO?

The active ingredient is betamethasone dipropionate. Other ingredients include butylated hydroxytoluene, cetostearyl alcohol, hydroxyethyl cellulose, methylparaben, mineral oil, oleyl alcohol, polyoxyl 20 cetostearyl ether, propylparaben, purified water, and sorbitan monostearate

aAvoid use on the face, scalp, axilla, groin, or other intertriginous areas.

IMPORTANT SAFETY INFORMATION

SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings. Avoid use on the face, scalp, axilla, groin or other intertriginous areas. Use of SERNIVO Spray is not recommended in pediatric patients as they are more susceptible to systemic toxicity. Allergic contact dermatitis may occur. The most common adverse reactions (≥1%) were application site pruritus, burning and/or stinging, pain, and atrophy. Local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. These are not all the possible side effects of SERNIVO Spray.
Please refer to Full Prescribing Information.

INDICATION AND USAGE

SERNIVO Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.

To report ADVERSE EVENTS, call 1-800-399-2561 or AE@encorederm.com, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. SERNIVO Prescribing Information. Encore Dermatology, Inc.
2. Gold LS, Jackson JM, Knuckles MLF, Weiss JS. Improvement in extensive moderate plaque psoriasis with a novel emollient spray formulation of betamethasone dipropionate 0.05%. J Drugs Dermatol. 2016;15(3):334-342. 3. Gold LS, Pariser D, Jackson JM. DFD-01, a midpotent betamethasone dipropionate 0.05% in an emollient-like spray formulation demonstrates similar efficacy to a super potent topical steroid for the treatment of moderate plaque psoriasis. Poster presented at: Annual Fall Dermatology Conference; November 3-6, 2016; Las Vegas, NV. 4. Zirwas M, Hebert A. Fast relief of itching in psoriasis with DFD-01, a novel medium-potency emollient spray formulation of betamethasone dipropionate 0.05%. Poster presented at: Winter Clinical Dermatology Conference; January 13-18, 2017; Kona, HI. 5. Kircik L, Okumu F, Kandavilli S, Sugarman J. Rational vehicle design ensures targeted cutaneous steroid delivery.
J Clin Aesthet Dermatol. 2017;10(2):12-19. 6. US Food and Drug Administration NDA # 208079. Dr. Reddy’s Laboratories, Princeton, NJ: Feb 2016.

Eligibility Rules

Patient Instructions: Redeem this coupon ONLY when accompanied by a valid presciption for SERNIVO® (betamethasone dipropionate) Spray, 0.05%. Commercially insured patients pay $0 for their prescription. Maximum reimbursement limits apply. This card must be presented at the time of fill for instant savings. Offer is good for commercially insured patients only. This coupon is good for up to 12 uses and is not transferable.
Please consult Full Prescribing Information for SERNIVO. Not valid for cash-paying patients or patients reimbursed by federal healthcare programs, including Medicare, Medicaid, Tri Care, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. 701 et. seq. state social service block grant programs under 42 U.S.C. section 1397 et. seq. or any other similar federal or state healthcare program. Void where prohibited by law, taxed or restricted. Void outside the United States. Void for residents of Massachusetts. Patient is responsible for reporting receipt of card program rewards to any private insurer that pays for or reimburses any part of the prescriptions filled with this card. Void if reproduced. It is illegal for any person to sell, purchase, or trade, or offer to sell, purchase or trade, or to counterfeit this card. Offer expires 12 months after initial use. Promius Pharma reserves the right to rescind, revoke or amend this offer at any time without notice.  

Download Co-Pay Card

THANK YOU

Thank you for signing up to receive news and information about SERNIVO. To fill out a sample request form, click the button below.

Download Sample Form Download Co-Pay Card

IMPORTANT SAFETY INFORMATION
SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing's syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-poten cy topical corticosteroids..